GlassScriptPhysician profile
Christy Ann Wust
NPI 1710519673
$1,954.02
in general payments reported to CMS, 2019-2025
15 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $504 · 2023: $505 · 2024: $368 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $585.12 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $457.50 | 2022-2024 | |
| Alkermes, INC. | $147.80 | 2025 | Vivitrol |
| Paratek Pharmaceuticals, INC. | $139.05 | 2023-2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $135.06 | 2022-2025 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $77.70 | 2022 | |
| Astellas Pharma US INC | $76.66 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $75.63 | 2022 | |
| Neurocrine Biosciences, INC. | $39.46 | 2025 | |
| Lilly USA, LLC | $25.15 | 2023 | Mounjaro |
| Exact Sciences Corporation | $18.79 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $18.36 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $17.15 | 2023 | Verquvo, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Wust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.